Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BYON4228 first-in-human dose-escalation and expansion study in relapsed/refractory CD20-positive B-cell non-Hodgkin lymphoma
NL-OMON59560Phase 1Completed
- Sponsor
- Byondis
- Start
- Jun 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of BYON4228 and rituximab in mature B-cell lymphoma (2 arms), sponsored by Byondis. Primary endpoint: Primary endpoint(s). Started Jun 2023; status: completed.
02
Drugs
BYON4228rituximab
03
Conditions
mature B-cell lymphoma
Beyond the preview
Go deeper on NL-OMON59560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59560.